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Abstract
The majority of cancer-related fatalities are due to metastatic disease [22]. In chemoradio-
therapy (CRT), chemotherapeutic agents are administered along with radiation to control the
primary tumor and systemic disease such as metastasis. This work introduces a mathemati-
cal model of CRT treatment scheduling to obtain optimal drug and radiation protocols with
the objective of minimizing metastatic cancer-cell populations at multiple potential sites while
maintaining a desired level of control on the primary tumor. A dynamic programming (DP)
framework is used to determine the optimal radiotherapy fractionation regimen and the drug
administration schedule. We design efficient DP data structures and use structural properties
of the optimal solution to reduce the complexity of the resulting DP algorithm. Also, we derive
closed-form expressions for optimal chemotherapy schedules in special cases. The results suggest
that if there is only an additive and spatial cooperation between the chemotherapeutic drug and
radiation with no interaction between them, then radiation and drug administration schedules
can be decoupled. In that case, regardless of the chemo- and radio-sensitivity parameters, the
optimal radiotherapy schedule follows a hypo-fractionated scheme. However, the structure of the
optimal chemotherapy schedule depends on model parameters such as chemotherapy-induced
cell-kill at primary and metastatic sites, as well as the ability of primary tumor cells to initiate
successful metastasis at different body sites. In contrast, an interactive cooperation between
the drug and radiation leads to optimal split-course concurrent CRT regimens. Additionally,
under dynamic radio-sensitivity parameters due to the re-oxygenation effect during therapy,
we observe that it is optimal to immediately start the chemotherapy and administer few large
radiation fractions at the beginning of the therapy, while scheduling smaller fractions in later
sessions. We quantify the trade-off between the new and traditional objectives of minimizing
the metastatic population size and maximizing the primary tumor control probability, respec-
tively, for a cervical cancer case. The trade-off information indicates the potential for significant
reduction in the metastatic population with minimal loss in the primary tumor control.
Keywords: Chemoradiotherapy, Multi-site Metastasis, Dynamic Programming,
Optimal Fractionation.
1 Introduction
Metastasis occurs when cancer cells spread from the primary tumor site to anatomically distant
locations. The process of cancer metastasis consists of the following steps: tumor cells detach
from the primary tumor site, invade a blood or lymphatic vessel, transit in the bloodstream, and
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extravasate from the blood vessels to distant sites where they proliferate to form new colonies. It
is thought that cancer cells evolve a special set of traits that improve their ability to carry out
this process [9, 16, 15]. Single or multi-site metastasis is a common occurrence in cancer patients.
For instance, bone metastasis occurs in up to 70% of patients with advanced prostrate or breast
cancer [45], and 20% of patients with carcinoma of the uterine cervix develop single (32%) or multi-
site (68%) metastasis at distant locations such as lymph nodes, lung, bone, or abdomen [8]. The
development of metastases significantly lessens the chances of successful therapy and represents a
major cause of mortality in cancer patients. For instance, only 20% of patients with breast cancer
[45] and less than 1% of patients with carcinoma of the uterine cervix [8] are still alive five years
after the discovery of metastasis.
Many researchers have used mathematical modeling and various optimization techniques to find
clinically relevant optimal radiation delivery schedules. The mathematical building block for the
majority of radiotherapy response modeling is the linear-quadratic (LQ) model [24]. This model
states that following exposure to d Gy of radiation, the surviving fraction of tumor cells is given by
e−αd−βd2 , where α and β are cell-specific parameters. In a conventional radiotherapy fractionation
problem, the goal is to maximize the biological effect of radiation on the tumor while inflicting the
least amount of healthy-tissue damage, which are evaluated using tumor control probability (TCP)
and normal-tissue complication probability (NTCP), respectively [56]. Some important questions
concern the best total treatment size, the best way to divide the total dose into fractional doses, and
the optimal inter-fraction interval times. An important result emerging from recent work is that
for low values of tumor [α/β], a hypo-fractionated schedule, where large fraction sizes are delivered
over a small number of treatment days, is optimal. However for large values of [α/β], a hyper-
fractionated schedule, where small fraction sizes are delivered over a large number of treatment
days, is optimal [39, 4, 2, 5].
For many inoperable tumors, radiotherapy alone is not enough to successfully control the pri-
mary tumor. For these tumors, chemoradiotherapy (CRT) is the standard of care, in which one
or several chemotherapeutic agents are administered along with radiation. There are at least two
basic mechanisms by which the combination of the two modalities may result in a therapeutic
gain. First, chemotherapy may be effective against (occult) systemic disease, such as metastasis.
This mechanism is called spatial cooperation. Second, the two modalities act independently (so-
called additivity) or dependently (so-called radio-sensitization) to enhance tumor cell-kill at the
primary site [51]. Recently, Salari et al. [48] studied changes in optimal radiation fractionation
regimens that result from adding chemotherapeutic agents to radiotherapy when maximizing TCP.
More specifically, they incorporated additivity and radio-sensitization mechanisms into the radi-
ation fractionation decision to identify corresponding changes in optimal radiation fractionation
schemes. Their results suggest that chemotherapeutic agents with only an additive effect do not
impact optimal radiation fractionation schemes; however, radio-sensitizers may change the optimal
fractionation schemes and in particular may give rise to optimal nonstationary schemes.
In our very recent work [3], we introduced a novel biologically driven objective function that
takes into account metastatic risk instead of maximizing TCP. We observed that when design-
ing optimal radiotherapy treatments with the goal of minimizing metastatic production, hypo-
fractionation is preferable for many parameter choices, and standard fractionation is only preferable
when the [α/β] value of the tumor is sufficiently large and the long-term metastasis risk (several
years after therapy) is considered. Our prior results [3] demonstrated a proof of concept that radi-
ation scheduling decisions have the potential to significantly impact metastatic risk. However, that
work excluded several important features in the modeling of advanced carcinomas.
2
First, we only considered single-site metastatic disease. However, it is well known that some
tumors, e.g., lung cancers, metastasize quickly to multiple sites, whereas others, such as breast and
prostate carcinomas, often take years to develop metastatic colonies and then only in a relatively
limited number of sites [29]. Importantly, metastatic colonies at different anatomical sites may
respond differently to anti-cancer drugs or have drastically different growth kinetics.
Another shortcoming of the previous work [3] was that the mathmatical model ignored the
growth of tumors at metastatic sites. In particular, [3] only looked at metastatic risk, which was
measured by the total number of successful metastatic cells produced and thus treated all successful
metastatic cells equally, regardless of what point in time they initiated metastatic lesions. However,
a more accurate model of the clinical situation allows for the metastatic cells to reproduce in their
new location [9]. Incorporating this important phenomenon now means that metastatic sites that
are initiated earlier are much more dangerous than metastatic lesions initiated late in the course
of the disease.
Third, our prior work [3] focused solely on radiotherapy. However, when studying the evolution
of metastatic disease under treatment, the role of chemotherapy is clearly paramount, given its
systemic nature. This has been born out in clinical trials where it has been observed that concurrent
CRT reduces the risk of distant metastasis compared to radiotherapy alone (e.g., see [54, 37]).
In the current work, we address these shortcomings by developing a mathematical model that
allows for multi-site metastatic disease with possible growth at each location and includes systemic
chemotherapy as a possible treatment.
Finally, our previous work only considered static tumor radio-sensitivity parameters (α and β)
of the LQ model over the course of radiotherapy. This ignores tumor re-oxygenation throughout
the course of treatment, which is known to enhance tumor radio-sensitivity [24, 55]. In this study,
we also consider evolving radio-sensitivity parameters due to tumor oxygenation and study the
resulting changes in optimal CRT regimens. This requires the development and implementation of
a dynamic programming (DP) algorithm with a six-dimensional state space. A naive application
of the state-discretization technique for this DP algorithm will be computationally intractable.
Hence, we develop approximation methods using efficient data structures to significantly lower the
required space to store state-space information. Additionally, we derive and use two mathematical
results on the structure of the optimal solution to reduce the computational complexity of our DP
algorithm.
In this work, we consider the problem of finding optimal radiotherapy dosing and a chemother-
apy regimen that minimizes the total expected number of metastatic tumor cells at multiple body
sites while keeping normal-tissue damage below clinically acceptable levels. To study the trade-off
between the conventional objective, maximizing TCP, and our novel approach of minimizing the
metastatic population, we consider an additional constraint requiring the tumor control associated
with the optimal regimen to exceed a user-specified percentage of that of conventional regimens.
To the best of our knowledge, the present study is the first to address optimal CRT fractionation
in the context of targeting multi-site metastatic disease and primary tumor control. We examine
the mathematical properties of the optimal fractionation scheme in the context of cervical tumors.
The remainder of this paper is organized as follows. In Section 2, we discuss a model with
static radio-sensitivity parameters for multi-site metastasis production and how it can be used to
develop a function that reflects metastatic production at different body locations. In Section 3,
we formulate an optimization model for the CRT fractionation problem, derive some mathematical
results regarding the properties of optimal regimens with constant α and β, extend our model
to incorporate dynamics of reoxygenation throughout the course of treatment, and develop a DP
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solution approach. In Section 4, we present numerical results for a situation involving cervical
cancer. Finally, we summarize and conclude the paper in Section 5.
2 Mathematical model of treatment and metastasis development
Consider a treatment regimen in which a radiation dose of di and a drug concentration of ci are
administered at treatment fraction i = 1, . . . , N . CRT treatment regimens are broadly divided into
three classes: neoadjuvant, concurrent, or adjuvant, depending on whether the chemotherapeutic
agents are administered before, during, or after the course of radiotherapy, respectively. We consider
a sufficiently large N to accommodate all possible regimens. The choice of sufficiently large N is
consistent with CRT clinical practice, where the duration of the therapy ranges between 6 to 10
weeks. Note that if N is small, then the solution space is limited to concurrent CRT regimens with
overlapping drug and radiation administration schedules, potentially excluding promising sequential
CRT regimens.
Our objective is to minimize total metastatic cell population produced by the primary tumor
at n different sites within the patient’s body at time T after the conclusion of the treatment,
while limiting the normal-tissue toxicity and ensuring a certain level of control over the primary
tumor. The time horizon [0, T ] consists of treatment days and a potentially long period of no
treatment, at the end of which total metastatic population is evaluated. In the following sections,
we first model the dynamics of the primary tumor and metastatic-cell populations in the presence
of chemoradiation cell-kill. Then we discuss a clinically established model used to quantify the
primary tumor control and normal-tissue toxicity. These models will be used to formulate the CRT
fractionation problem.
2.1 Modeling primary tumor population growth
We start by modeling the population of primary tumor cells at time t as a function of radiation
dose using the well-known LQ model, originated from clinical observations that survival curves of
irradiated cell lines follow a linear-quadratic fit on a logarithmic scale [24]. According to the LQ
model, the surviving fraction (SFRT) of tumor cells after a single exposure to a radiation dose of d
is
SFRT(d) = exp
(−αd− βd2)
where α and β are tumor radio-sensitivity parameters.
To account for the cytotoxic effect of chemotherapeutic agents on the primary tumor popula-
tion, we consider the two action mechanisms of additivity and radio-sensitization associated with
CRT and incorporate them into the LQ model. Additivity refers to an added tumor cell-kill due
to chemotherapeutic agents, assuming no interaction with radiation. Radio-sensitization, on the
other hand, refers to an enhancement in the radiation-induced cell-kill, caused by chemothera-
peutic agents [49]. Additivity is incorporated into the LQ model by adding a linear term of the
chemotherapy drug’s concentration, denoted by c, to the exponent of the LQ model. This is mo-
tivated by the observations that survival curves of cell lines that are exposed to chemotherapeutic
agents follow an exponential form in terms of the drug’s concentration [50, 33]. To accommodate
radio-sensitization, we use the approach suggested in [48] in which a multiplicative term of the
radiation dose and chemotherapy drug’s concentration is added to the exponent of the LQ model.
This is based on clinical observations that radio-sensitizers increase the linear term of the LQ model
without causing a considerable change in the quadratic term [12, 19]. Hence, the total fraction of
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surviving cells after incorporating additivity and radio-sensitization (SFCRT) can be modified as
SFCRT(d, c) = exp
(−αd− βd2 − θc− ψdc)
where θ and ψ are chemo-sensitivity parameters associated with the additivity and radio-
sensitization terms, respectively.
The choice of tumor-growth function is strongly driven by the size of cancer being modeled.
Exponential growth is a good model for small-sized tumors. However, limitations of the availability
of nutrients, oxygen, and space imply that exponential growth is not appropriate for the long-term
growth of solid tumors, suggesting alternative formulations such as Gompertz or logistic models.
The current view of tumor-growth kinetics during therapy is based on the general assumption
that tumor cells grow exponentially due to the small population [24]. Here, we also assume that
the tumor is small enough and that it grows exponentially with a time lag during the course of
the treatment, known as tumor kick-off time. In particular, we are interested in the long-term
metastatic risk associated with a CRT regimen evaluated at any time point between the conclusion
of therapy and the local recurrence. During this time period, the primary tumor has not yet reached
a clinically detectable size again and thus is sufficiently small enough to model with an exponential
function.
Consider a CRT regimen (di, ci) (i = 1, . . . , N) that delivers a radiation dose of di, measured
in Gy, and a chemotherapy dose of ci, measured in milligrams per squared meter of body area, on
day i = 1, . . . , N . The primary-tumor population size at time t ∈ [0, T ], denoted by Xt, can then
be computed by
Xt =
X0e
−∑ti=1(αdi+βd2i+θci+ψdici)+ ln 2τd (t−Tk)+ , t ≤ N
X0e
−∑Ni=1(αdi+βd2i+θci+ψdici)+ ln 2τd (t−Tk)+ , t > N (2.1)
where X0 is the initial tumor population, Tk is the tumor kick-off time, and τd shows the tumor
doubling time in units of days.
2.2 Modeling metastatic population growth
We adopt a stochastic model used by other studies [28, 26, 27] to describe the metastatic production
and formation process. Here, we provide details of this model. The model assumes that only a
fraction of the primary tumor cells are capable of producing successful metastatic cells and that
these cells do so at rate ν. This fraction is dictated by the fractal dimension of the blood vessels
infiltrating the tumor, which we denote by ξ ∈ [0, 1] [30]. For example, if we assume that the tumor
is roughly spherical and all cells on the surface are capable of metastasis, then we would take
ξ = 2/3; however, if we assume only the cells along the boundary of a one-dimensional blood vessel
are capable of metastasis, then we would set ξ = 1/3 (see [28] for a more detailed discussion and
estimation of this parameter). A non-homogeneous Poisson process with intensity function νXξt
is then used to describe the successful metastatic-cell production. Each successful metastatic cell,
independent of other cells, will initiate a metastatic colony at site i (i = 1, . . . , n) with probability
pi (
∑n
i=1 pi = 1). Finally, it is assumed that the probability of secondary metastasis, which is
the formation of new metastasis originating in other metastatic colonies, is negligible. Therefore,
thinning the original Poisson process tells us that metastasis formation at site i follows a non-
homogeneous Poison process with rate bi(t) = piνX
ξ
t .
We model the growth of each metastatic lesion using a non-homogeneous branching process
with a rate dependent on time t and the metastasis site. More specifically, the birth and death
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rates at site i (i = 1, . . . , n) are denoted by ui(t) and vi(t), respectively. This is similar to the
modeling approach taken in [23], which used multi-type branching processes to study metastasis
and then applied the work to study pancreatic cancer data. It should be noted that this work
were able to successfully fit this model to patient data. We consider the growth rate of metastatic
cells µi(t) = ui(t) − vi(t) in the absence of chemotherapeutic agents as a positive value that is
constant with respect to time (µi(t) = µi). During chemotherapy, we assume that the growth rate
of metastatic cells decreases linearly as a function of the magnitude of the last dose of chemotherapy
drug administrated [40]. Written mathematically we have
µi(t) =
{
µi − ωicbtc, t ≤ N
µi, t ∈ (N,T ]
, i = 1, . . . , n (2.2)
where ωi is a positive constant, depending on heterogeneity in drug concentrations among different
sites and sensitivity of tumor cells to the chemotherapy at the ith site.
If we have a total evaluation horizon of time T , then the expected number of total metastatic
cells at site i is given by the convolution (see [17])
Ri(T ) =
∫ T
0
bi(t) exp
(∫ T−t
0
µi(η + t)dη
)
dt.
Our goal is to determine an optimal chemo- and radiotherapy fractionation scheme that minimizes
the total expected number of metastatic tumor cells at time T at n body sites, i.e.,
R(T ) =
n∑
i=1
Ri(T ) = ν
n∑
i=1
pi
∫ T
0
Xξt exp
(∫ T−t
0
µi(η + t)dη
)
dt. (2.3)
Notice that in order to minimize R(T ), it is sufficient to optimize R(T )/ν, and there is no need to
know parameter ν, which is difficult to estimate.
2.3 Modeling primary tumor control and normal-tissue toxicity due to radiation
The notion of biologically equivalent dose (BED), originally motivated by the LQ model, is
used in clinical practice to quantify the biological damage caused by a given radiotherapy regimen
in a structure. More specifically, the BED for a radiotherapy regimen consisting of N treatment
fractions in which radiation dose di is administered in fraction i (i = 1, . . . , N) is given by
BED =
N∑
i=1
di
(
1 +
di
[α/β]
)
(2.4)
where [α/β] is a structure-specific radio-sensitivity parameter. Several clinical studies have asso-
ciated different BED values, independent of the number of fractions and the radiation dose per
fraction di (i = 1, . . . , n), to TCP and NTCP values calculated, based on clinical data [18]. We will
use BED to measure and compare the primary tumor control and the normal-tissue toxicity of the
radiotherapy schedule di (i = 1, . . . , N) in different CRT treatments.
3 Optimization model and solution approach
Our goal is to determine the optimal radiation dose vector ~d∗ = {d∗1, . . . , d∗N} and optimal
chemotherapy drug concentration vector ~c∗ = {c∗1, . . . , c∗N} that minimize the total expected num-
ber of metastatic cancer cells at time T at n different anatomical sites. We do not consider the
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metastatic dissemination prior to the start of the treatment course. One reason for this is that it
is difficult to estimate the total life history of a tumor prior to diagnosis. In addition, our model is
primarily intended for locally advanced cancer cases, whereas metastasis formation typically occurs
in later stages of the disease once the tumor has reached a significantly large size [25].
We start by computing∫ T−t
0
µi(η + t)dη =
∫ T
t
µi(s)ds =
{
µi · (T − t)− ωi
(
cbtc(dte − t) +
∑N
j=dte cj
)
, t < N + 1
µi · (T − t), t ∈ [N + 1, T ]
with notation c0 = 0 and
∑N
j=dte cj = 0 for t > N . For computational ease, we assume an equal
metastasis production for t ∈ [btc, dte), which is evaluated at time btc. Specifically we replace
Xt with X
−
t and µi · (T − t) − ωi
(
cbtc(dte − t) +
∑N
j=dte cj
)
with µi · (T − t) − ωi
∑N
j=btc cj for
0 ≤ t < N + 1, where X−t is the number of cells immediately before the delivery of doses dt and
ct (note that X
−
0 = X0). In addition, we use a similar approximation approach as that taken in
[3], which uses a summation rather than an integral during therapy. To summarize, we make the
following approximation:
R(T )/ν ≈
n∑
i=1
pi
N+1∑
t=0
(X−t )
ξ exp
µi · (T − t)− ωi T∑
j=t
cj
+ ∫ T
N+1
Xξt e
µi·(T−t)dt
 . (3.5)
Substituting Xt from (2.1) into (3.5) yields
R(T )/ν ≈ f(~d,~c) + g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
ct,
N∑
t=1
dtct
)
where
f(~d,~c) = Xξ0
n∑
i=1
pie
µiT
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αdj+βd
2
j+θcj+ψdici)− ln 2τd (t−Tk)
+
)
−µit−ωi
∑T
j=t cj (3.6)
and
g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
ct,
N∑
t=1
dtct
)
= Xξ0e
−ξΓ
n∑
i=1
pie
µiT
e
−(µi−ξ ln 2τd )(N+1) − e−(µi−ξ
ln 2
τd
)T
µi − ξ ln 2τd
(3.7)
where
Γ =
N∑
t=1
(αdt + βd
2
t + θct + ψdtct) +
ln 2
τd
Tk.
Note that in (3.6), the summation inside the exponential for t = 0, 1 is zero, i.e.,
t−1∑
j=1
(αdj + βd
2
j + θcj + ψdjcj) = 0
for t = 0, 1, and we assume Tk < N , which is typically the case for all disease sites. We now consider
the fractionation problem in terms of decision variables of radiation dose di and drug concentration
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ci at fraction i = 1, . . . , N , which leads to a minimal metastasis population size while maintaining
acceptable levels of normal tissues damage.
minimize
dt,ct≥0
f(~d,~c) + g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
ct,
N∑
t=1
dtct
)
(3.8)
s.t.
N∑
t=1
γjdt
(
1 +
γjdt
[α/β]j
)
≤ BEDj , j = 1, . . . ,M (3.9)
N∑
t=1
dt
(
1 +
dt
[α/β]
)
≥ %× BEDstd (3.10)
N∑
t=1
ct ≤ Cmax (3.11)
dt ≤ dmax, t = 1, . . . , N (3.12)
ct ≤ cmax, t = 1, . . . , N (3.13)
The objective function evaluates the total metastatic population (divided by ν) at time T
at n different body organs. Constraints (3.9) and (3.11) are toxicity constraints associated with
radiotherapy and chemotherapy, respectively. More specifically, we use the BED model in (2.4)
to constrain the radiation side effects in the surrounding healthy structures around the tumor
[24]. In doing so, we assume that there are M healthy tissues in the vicinity of the tumor, and a
dose d results in a homogeneous dose γjd in the jth normal tissue, where γj is the sparing factor.
Parameter [α/β]j represents the BED parameter, and BEDj specifies the maximum BED allowed
in the jth healthy tissue. We limit the maximum cumulative chemotherapy dose by Cmax, which is
the total drug dose that can be safely delivered to a patient over the period of treatment, measured
in milligrams/meter squared [38]. Inequalities (3.12) and (3.13) limit the maximum allowable daily
radiation dose and chemotherapy drug concentration, respectively, where dmax and cmax show the
maximum tolerable dose, measured in Gy and milligrams/meter squared, respectively, that can be
delivered in a single day [38].
Finally, constraint (3.10) guarantees that tumor BED imposed by the optimal schedule is greater
than or equal to % × 100 percent of the tumor BED realized by the standard schedule. Note that
TCP is an increasing function of tumor BED for a homogeneous radiation dose, and thus TCP and
tumor BED maximization are equivalent. The parameter 0 ≤ % ≤ 1 is an input to our model and
characterizes the trade-off between maximizing TCP and minimizing metastatic cell population
(see, e.g., [11] for a review of optimization methods to characterize the trade-off between the
two objectives). If the primary cause of cancer-related death in a specific tumor is metastatic
dissemination (e.g. pancreatic or cervical cancer), then a relatively small value of % (e.g., 70%)
may be used. On the other hand, if the primary tumor may cause death (e.g., lung cancer), then
a larger value of % will be used (e.g., 98%).
The formulation (3.8)–(3.13) is a nonconvex, quadratically constrained program. Such prob-
lems are computationally difficult to solve in general. In the rest of this section, we first derive
some mathematical results regarding the structure of the optimal solution of (3.8)–(3.13) and then
develop a DP algorithm to solve the problem.
We start by discussing an important property of the optimal chemotherapy dose vector.
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Lemma 1. Let the optimal drug vector of problem (3.8)–(3.13) be ~c∗ = {c∗1, . . . , c∗N}; then in
optimality, we have
N∑
t=1
c∗t = Cmax.
The proof is in Appendix A. Lemma 1 states that any optimal solution to (3.8)–(3.13) yields
a chemotherapy regimen with the maximum dose allowed. Using the result of Lemma 1, we can
rewrite function f(~d,~c) as
f(~d,~c) = Xξ0
n∑
i=1
pie
µiT
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αdj+βd
2
j+(θ−ωi/ξ)cj+ψdjcj)− ln 2τd (t−Tk)
+
)
−µit−ωiCmax . (3.14)
3.1 Developing DP solution method
Using the new form of function f(~d,~c) derived in (3.14), we develop a DP algorithm to find the op-
timal daily radiation and chemotherapy doses. Stages of the DP algorithm correspond to treatment
days t ∈ {1, . . . , T}. At stage t, the state of the system is characterized by At = {Ut, Vt, St,Wt},
where Ut and Vt are the cumulative dose and cumulative dose squared, respectively, St is the cumula-
tive chemotherapy dose, and Wt is the cumulative product of daily radiotherapy and chemotherapy
doses, all calculated after the delivery of radiation and chemotherapy on day t. The control vari-
ables at stage t are the radiation and chemotherapy doses administered during that stage. Given
control variables (dt, ct), the state of the system is updated according to
Ut = Ut−1 + dt, Vt = Vt−1 + d2t , St = St−1 + ct, Wt = Wt−1 + dtct.
Let Jt : R4 → R be the cost-to-go function at stage t (t = 1, . . . , T ). Using the functions introduced
in (3.7) and (3.14), the forward recursion of our DP algorithm can be written as
Jt(At) =
{
mindt,ct≥0 Jt−1(At−1) + L(dt, ct,At−1), 1 ≤ t ≤ N − 1
mindt,ct≥0 Jt−1(At−1) + g(Ut−1 + dt, Vt−1 + d2t , Cmax,Wt−1 + dtct), t = N
where
L(dt, ct,At−1) = Xξ0
n∑
i=1
pie
−ξ×Ψt,i+µi·(T−t)−ωiCmax
Ψt,i = α(Ut−1 + dt) + β(Vt−1 + d2t ) + (θ − ωi/ξ)(St−1 + ct) + ψ(Wt−1 + dtct)−
ln 2
τd
(t− Tk)+
with initial conditions A0 = {0, 0, 0, 0} and J0(A0) = Xξ0
∑n
i=1 pie
µiT−ωiCmax . We set the function
JN (AN ) to be ∞ if
UN +
β
α
VN < %× BEDstd
and Jt(At), t = 1, . . . , N to be ∞, if any of the following constraints is violated:
γjUt +
γ2j Vt
[α/β]j
> BEDj , j = 1, . . . ,M ; or St > Cmax.
A standard approach to solving Bellman’s equations with forward recursion is to discretize the
state space and use a linear interpolation of appropriate discretized values to increase the accuracy
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of cost-to-go function estimations at intermediate state values [3, 48, 5]. Depending on the size
of the state space, a naive implementation of this approach may be computationally intractable
due to the large number of possible discretized states, known as the curse of dimensionality. To
alleviate the computational burden of the discretization approach in our DP framework, we employ
a dynamic table data structure to only store the information related to feasible states. Columns
and rows of this table correspond to state attributes and feasible states at different DP stages,
respectively. This leads to a significant reduction in the number of discretized states considered.
The details of this implementation is in Appendix B.
In the rest of this section, we study two special cases of the proposed model. The first special
case considers CRT regimens in the absence of radio-sensitization and derives a closed-form solution
for the optimal chemotherapy schedule, which significantly reduces the computational complexity
of the DP algorithm. The second case considers a new version of the proposed model in which
tumor radio-sensitivity parameters vary during the course of the treatment.
3.2 Optimal CRT regimens in the absence of radio-sensitization
Several cytotoxic agents, such as temozolomide, are suggested to only have an additive effect
[10]. This corresponds to those chemotherapeutic agents that exhibit insignificant or no radio-
sensitization, which translates to ψ = 0 in tumor population dynamics introduced in (2.1). In this
section, we solve the problem (3.8)–(3.13) for the special case of negligible radio-sensitization effect
(ψ = 0). First, we use the new form of function f(~d,~c) stated in (3.14) and show an interesting
property of the optimal structure of radiation and chemotherapy schedules.
Lemma 2. Let the optimal dose and drug vector of problem (3.8)–(3.13) be ~d∗ = {d∗1, . . . , d∗N} and
~c∗ = {c∗1, . . . , c∗N}, respectively; if ψ = 0, then, in optimality, we have
d∗1 ≥ d∗2 ≥ · · · ≥ d∗N
and {
c∗1 ≥ c∗2 ≥ · · · ≥ c∗N , if θξ ≥ maxi=1,...,n ωi
c∗1 ≤ c∗2 ≤ · · · ≤ c∗N , if θξ < mini=1,...,n ωi.
The proof is in Appendix C. In Lemma 2, we specify the general structure of the optimal CRT
regimen in the absence of any radio-sensitivity effect. In the following result, we find the optimal
chemotherapy drug vector for two special cases.
Theorem 1. Let the optimal drug vector of problem (3.8)–(3.13) be ~c∗ = {c∗1, . . . , c∗N}; if ψ = 0;
then ~c∗ takes one of the following two forms, if we have θξ ≥ maxi=1,...,n ωi or θξ < mini=1,...,n ωi:
1. θξ ≥ maxi=1,...,n ωi: Optimal schedule is given by c∗i = cmax for i = 1, . . . , k, c∗k+1 = Cmax −
kcmax and c
∗
i = 0 for i = k + 2, . . . , N , where k = bCmax/cmaxc.
2. θξ < mini=1,...,n ωi: Optimal schedule is given by c
∗
i = cmax for i = N − k + 1, . . . , N ,
c∗N−k = Cmax − kcmax and c∗i = 0 for i = 1, . . . , N − k − 1, where k = bCmax/cmaxc.
The proof is in Appendix D. The following three important observations are made for optimal
CRT treatment regimens based on the results of Lemma 2 and Theorem 1. Note that in the
following, we assume that radio-sensitization effect is negligible.
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Remark 1. The non-increasing order of the optimal radiation dose vector obtained in Lemma 2
suggests that it is always optimal to immediately start the radiotherapy treatment. Furthermore, it is
optimal to immediately initiate chemotherapy if θξ ≥ maxi=1,...,n ωi, or to postpone chemotherapy
until the end of the treatment if θξ < mini=1,...,n ωi, suggesting a concurrent and adjuvant CRT
regimen, respectively. Hence, Lemma 2 tells us that it is never optimal to use neoadjuvant CRT
regimens, which is consistent with clinical observations [21](see conclusion for more discussion).
Remark 2. The resulting radiotherapy fractionation schedules for minimizing total metastatic
cancer cells suggest a non-increasing radiation fractionated structure, which is due to the structure
of the model. Metastatic cells initiated at distant locations are not killed by radiotherapy doses.
Thus, in order to minimize the metastatic cell population using radiation, it is necessary to quickly
reduce the primary tumor cell population since this is the source of metastatic lesions. Also, note
that given the growth of metastatic lesions, we are particularly concerned with metastatic lesions
created early in the course of therapy.
Remark 3. The resulting chemotherapy fractionation schedules for minimizing total metastatic
cancer cells suggest a hypo-fractionated structure concentrated at the beginning or the end of the
schedule. This is due to the fact that if the combined effect (θξ) of chemotherapy-induced cell-
kill (θ) and the fraction of cells capable of metastasis in the primary tumor (ξ) are larger than
the chemotherapy-induced metastatic cell-kill at all distant locations (maxi=1,...,n{ωi}), then we
consider the primary tumor cell population as dangerous, due to the inability of chemotherapy to
control the metastatic cell populations. Hence, it is preferable to target the primary tumor and
reduce its size as quickly as possible. However, if the effect of the chemotherapeutic agents on all
distant metastatic sites (mini=1,...,n{ωi}) is larger than the product of chemotherapy-induced cell-
kill (θ) and the fraction of cells that are capable of metastasis in the primary tumor (ξ), then we
consider that the chemotherapeutic agents are more effective in controlling metastatic disease than
the primary tumor control. Hence, we prefer to administer chemotherapy at the end of treatment
when we can target the accumulated metastatic cells.
Finally, we establish a result that describes the closed-form solution of the optimal radiotherapy
schedule for a special case in which β = 0 in equation (2.1), [α/β]j → ∞ (j = 1, . . . ,M) in
inequalities (3.9), and [α/β] → ∞ in inequality (3.10). The special case entails the use of a linear
log-survival model, rather than LQ, to describe tumor cell-kill. Also, it implies the use of physical
dose, rather than BED, to measure normal-tissue toxicity and primary tumor control. This case is
motivated by the fact that tissue response to small radiation doses is dominated by the linear term
[47, 1], which is applicable to our model when dmax is sufficiently small (around 2 Gy [41]).
Proposition 1. If we assume that radiation-induced tumor cell-kill has a linear form, i.e., β = 0
and radiation-induced toxicity in normal-tissue j (j = 1, . . . ,M) and the primary tumor control are
evaluated using the physical dose, i.e., [α/β]j →∞ and [α/β]→∞, then the optimal radiotherapy
schedule is given by d∗i = dmax for i = 1, . . . , k, d
∗
k+1 = Dmax−kdmax and d∗i = 0 for i = k+2, . . . , N ,
where k = bDmax/dmaxc and Dmax = minj=1,...,M {BEDj/γj}.
In order to explain this result, we first note that the inequality
∑N
t=1 dt ≤
minj=1,...,M {BEDj/γj} defines the set of feasible regions associated with the radiation-induced
toxicity constraints in normal tissues, and thus we can remove the remaining M − 1 redundant in-
equalities from the constraint set. Then, an almost identical argument as used in proof of Theorem
1 for the case of θξ ≥ maxi=1,...,n ωi can be implemented to derive the optimal dose vector.
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If either of the conditions outlined in Theorem 1 are applicable, then the optimal chemotherapy
schedule exists in closed form. It then remains to find the optimal radiation doses, which can be
determined using a reduced version of the DP algorithm developed in Section 3.1 and considering
only a 2D state space consisting of Ut and Vt. Otherwise, the optimal solution can be obtained
using the DP algorithm with a 3D state space consisting of Ut, Vt, and St, since there is no radio-
sensitization in this case.
3.3 Dynamic tumor radio-sensitivity parameters
The degree of tumor oxygenation is a crucial determinant of the effectiveness of radiotherapy. In
particular, an insufficient supply of oxygen in tumor, known as hypoxia, causes radio-resistance in
most tumors, thereby adversely affecting the cancer treatment outcome in solid tumors [57]. It
is suggested that radiation fractionation alleviates tumor hypoxia through the phenomenon of re-
oxygenation, the process by which hypoxic cells surviving a given radiation fraction become more
oxygenated and thus more susceptible to radiation prior to the next fraction [24]. In this section, we
account for the tumor re-oxygenation effect by explicitly modeling the dependence of tumor radio-
sensitivity parameters on the tumor oxygen level. To this end, we first review a mathematical
model for calculating oxygen-dependent radio-sensitivity parameters. We then extend the tumor
population dynamics introduced in Section 2.1 to the case of dynamic radio-sensitivity parameters.
Finally, we propose an efficient DP algorithm to solve the revised model.
The common approach to modeling the evolution of radio-sensitivity parameters is to incor-
porate the concept of the oxygen enhancement ratio (OER), which models the dependence of
radio-sensitivity parameters on tumor oxygen partial pressure as follows [57, 46]:
αt =
αmax
OERα
(
yt ×OERα +K
yt +K
)
, βt =
βmax
OER2β
(
yt ×OERβ +K
yt +K
)2
(3.15)
In the equations above, αmax and βmax are radio-sensitivity parameters under well-oxygenated
conditions, and yt denotes the average tumor oxygen partial pressure at time t. Additionally,
OERα, OERβ, and K are the fitted parameters of the OER model. To model the evolution of
tumor oxygen partial pressure, we consider a spherical tumor, the radius of which, denoted by rt,
changes throughout the treatment course as a result of radiation and chemotherapy cell-kill as well
as tumor repopulation. In particular, assuming a constant tumor-cell density per unit volume,
denoted by ρ, we express the radius of the tumor prior to the start of treatment session t as a
function of the tumor population size, that is, rt =
3
√
3Xt−1
4piρ [55]. We then assume a simple model
in which the average oxygen partial pressure yt in (3.15) is linearly proportional to the radius of
the spherical tumor, that is, yt ∝ rt. This assumption is motivated by clinical studies indicating
that large tumors have large hypoxic regions [31]. Substituting Xt−1 from equation (2.1), we can
express the average tumor oxygen partial pressure on treatment session t as
yt = ymax − ι× 3
√
3X0
4piρ
exp
(
−1
3
t−1∑
i=1
(
αidi + βid
2
i + θci + ψdici
)
+
ln 2
3τd
(t− Tk)+
)
(3.16)
where ymax is the maximum average oxygen partial pressure, usually achieved toward the end of
treatment when the tumor radius is sufficiently small, and ι is the model parameter representing
the increase in average oxygen partial pressure per unit reduction in tumor radius. Note that the
value ymax−ι× 3
√
3X0
4piρ represents the average oxygen partial pressure for the tumor at the beginning
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of the therapy, which depends on the initial tumor size and the tumor oxygenation level. Hence,
we can use the average tumor oxygenation level of an arbitrary tumor at the beginning and end of
treatment to calibrate our model.
Equation (2.1) describing the tumor population size needs to be updated to account for dynamic
tumor radio-sensitivity parameters as follows:
Xt =
X0e
−∑ti=1(αidi+βid2i+θci+ψdici)+ ln 2τd (t−Tk)+ , t ≤ N
X0e
−∑Ni=1(αidi+βid2i+θci+ψdici)+ ln 2τd (t−Tk)+ , t > N.
This changes the objective function of problem (3.8)–(3.13) to
fˆ(~d,~c, ~α, ~β) + gˆ
(
N∑
t=1
αtdt,
N∑
t=1
βtd
2
t ,
N∑
t=1
ct,
N∑
t=1
dtct
)
where
fˆ(~d,~c, ~α, ~β) = Xξ0
n∑
i=1
pie
µiT
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αjdj+βjd
2
j+(θ−ωi/ξ)cj+ψdjcj)− ln 2τd (t−Tk)
+
)
−µit−ωiCmax
gˆ =
(
N∑
t=1
αtdt,
N∑
t=1
βtd
2
t ,
N∑
t=1
ct,
N∑
t=1
dtct
)
= Xξ0e
−ξΓˆ
n∑
i=1
pie
µiT
e
−(µi−ξ ln 2τd )(N+1) − e−(µi−ξ
ln 2
τd
)T
µi − ξ ln 2τd
Γˆ =
N∑
t=1
(αtdt + βtd
2
t + θct + ψdtct) +
ln 2
τd
Tk.
To solve the formulation in (3.8)–(3.13) with the modified objective function using the DP approach,
we need to store two additional state variables, Uˆt =
∑t−1
i=1 αtdt and Vˆt =
∑t−1
i=1 βtd
2
t . This leads to
a 6D state space characterized by Bt = {Ut, Vt, St,Wt, Uˆt, Vˆt}. The cost-to-go functions Jˆt : R6 → R
for the new state space are defined as
Jˆt(Bt) =
{
mindt,ct≥0 Jˆt−1(Bt−1) + Lˆ(dt, ct,Bt−1), 1 ≤ t ≤ N − 1
mindt,ct≥0 Jˆt−1(Bt−1) + gˆ(Uˆt−1 + dt, Vˆt−1 + d2t , Cmax,Wt−1 + dtct), t = N
where
Lˆ(dt, ct,Bt−1) = Xξ0
n∑
i=1
pie
−ξ×Ψˆt,i+µi·(T−t)−ωiCmax
Ψˆt,i = Uˆt−1 + αtdt + Vˆt−1 + βtd2t + (θ − ωi/ξ)(St−1 + ct) + ψ(Wt−1 + dtct)−
ln 2
τd
(t− Tk)+.
Tumor radio-sensitivity parameters αt and βt (t = 1, . . . , N) used in the cost-to-go functions can
be computed using equations (3.15)–(3.16). The dynamic table data structure employed in our
DP implementation significantly reduces the computational and space requirements of our DP
algorithm with a 6D state space. Details of the DP algorithm and implementation for the 6D state
space are provided in Appendix E.
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4 Numerical results
In this section, we test the performance of our formulation and solution methods on a locally
advanced cervical cancer case. We consider the toxicity effects of radiotherapy in three different
organs-at-risk(OAR): bladder, small intestine, and rectum [44], using the BED model introduced
in (2.4). A standard fractionated treatment for cervical cancer delivers 45 Gy to the tumor over
five weeks (25 working days). The maximum tolerated doses for each organ at risk is computed
based on this standard fractionation scheme (1.8 Gy × 25).
Treatment days comprise a course of external beam radiotherapy and chemotherapy adminis-
tration, followed by a short rest period lasting Nr days, and low-dose-rate brachytherapy with a
dose rate of R Gy per day delivered within Nb days. This treatment sequence is motivated by
the combined-modality treatment protocols used in clinical practice for cervical cancer, which of-
ten involve adjuvant brachytherapy. Equation (2.1) can be adjusted to account for the additional
brachytherapy as follows (see [43] for more details):
Xt =

X0e
−∑ti=1(αdi+βd2i+θci+ψdici)+ ln 2τd (t−Tk)+ , t ≤ N +Nr
X0e
−∑Ni=1(αdi+βd2i+θci+ψdici)−egR(t−N−Nr)(αN+2βNR/σ)+ ln 2τd (t−Tk)+ , N +Nr < t ≤ N +Nr +Nb
X0e
−∑Ni=1(αdi+βd2i+θci+ψdici)−egRNb(αN+2βNR/σ)+ ln 2τd (t−Tk)+ , t > N +Nr +Nb
(4.17)
where σ is the monoexponential repair rate of sublethal damage, and eg represents the effects of dose
gradients around the brachytherapy sources (see [43, 13]). We assume that low-dose brachytherapy
is performed in two days within one week after the completion of pelvic external radiotherapy
[43]. Note that this assumption does not affect the optimal solution, and our result still applies to
different brachytherapy schedules.
The standard chemotherapy agents used in locally advanced cervical tumors are cisplatin, given
at low daily doses, and fluorouracil (5-FU), given at high daily doses [34, 54]. We assume that
cisplatin, when delivered at low doses, only augments the effects of radiotherapy through radio-
sensitization without any independent cytotoxic effect [7, 52]. Hence, the LQ parameter α in (4.17)
is substituted with α + κccis, where ccis shows the average daily dose of cisplatin, as discussed in
Section 2.1. cisplatin is usually administered intravenously at a dose of 40 mg per square meter
of body-surface area (mg/m2) per week [34]; therefore, we set the daily dose ccis = 8 mg/m
2.
The agent 5-FU administrated at high doses is considered to have an inherent cytotoxic activity
acting as a systemic therapeutic agent [49]. The standard concurrent CRT protocol for cervical
cancer consists of administrating a 5-FU dose of 1, 000 mg/m2 per day for 8 days [42]. Hence,
we set the maximum daily dose of 5-FU to be cmax = 1, 000 mg/m
2 and the total dose to be
Cmax = 8, 000 mg/m
2.
We set N to be 25 days (five weeks, considering weekends as breaks) since 5-FU is given
concurrently with radiotherapy. We employ the calibration method discussed in [43] to estimate
the values of parameters κ, ψ, and θ associated with radio-sensitization of cisplatin and 5-FU and
additivity of 5-FU, respectively, from clinical trial studies. In particular, to estimate parameter
κ, we use the clinical trial study reported by [34] to compare the progression-free survival rate of
patients treated with radiotherapy alone, denoted by TCPRT, against that of patients treated with
radiotherapy plus cisplatin, denoted by TCPCRT. This yields the following estimation for parameter
κ (see [43] for more details):
κ = − ln(ln(TCPCRT)/ ln(TCPRT))
ccis ×
∑N
t=1 dt
.
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Similarly, we compare the progression-free survival rates of radiotherapy alone against radiotherapy
plus 5-FU regimens reported by two different clinical studies to estimate parameters θ and ψ [42, 14].
This yields the following two equations for estimating parameters θ and ψ:
θ
N∑
i=1
c
(m)
i + ψ
N∑
i=1
d
(m)
i × c(m)i = − ln
 ln
(
TCP
(m)
CRT
)
ln
(
TCP
(m)
RT
)
 m = 1, 2.
in which the regimens used in the two studies are indexed by m = 1, 2.
All model parameters are summarized in Table 1. Based on the survival rates reported in [42]
and [14], we estimated an insignificant value for parameter ψ (i.e., ψ ≈ 0). Note that ψ is associated
with 5-FU and does not include the radio-sensitization effect of cisplatin. To study the structure
of the optimal solution in the presence of radio-sensitization, we use the same radio-sensitization
parameter value used for cisplatin (i.e., ψ = κ). To fully explore how the structure of the optimal
solution relates to the optimal conventional fractionation regimes in different scenarios, we consider
a wide range of values for the parameters [α/β]. There is a significant amount of debate as to
whether or not the LQ model applies to large doses [35, 6]. In view of this, we set dmax to be 5 Gy.
Structure Parameters Values Source
Cervical Tumor
α 0.43 Gy−1 [56]
[α/β] {3,12,20} Gy
κ 3.21× 10−3 m2/(mg×Gy) [34]
θ 7.15× 10−5 m2/mg [42, 14]
ψ {0, 3.21× 10−3} m2/(mg×Gy) [34, 42, 14]
R 20 Gy/day [43]
eg 1.16 [43]
σ 12 day−1 [43]
τd 4.5 days [53]
Tk 21 days [43]
X0 10
9 cells [43]
ι 10.48 mmHg [36]
ymax 26 mmHg [36]
Bladder
[α/β] 2.00 [56]
γ 60.48% [44]
Small Intestine
[α/β] 8.00 [32]
γ 34.24% [44]
Rectum
[α/β] 5.00 [56]
γ 46.37% [44]
Table 1: Tumor and normal tissue parameters
Distribution of the most common sites of cervical cancer metastases is outlined in Table 2
(see [8]). Metastases often grow at the same rate as the primary tumor [20]; hence, it is natural
to assume that µ1 = · · · = µn = ln 2τd . Although distant metastases may appear any time after
treatment, approximately 88% of multi-organ metastases in cervical cancer occur within three
years of the conclusion of treatment [8]. Hence, we set parameter T to three years. Parameter ωi
represents the reduction in metastatic cell growth rate at site i in relation to the chemotherapy dose
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administrated and has a unit of mg/m2 per day. There is a lack of reliable clinical data on the rate
of chemotherapy-induced cell-kill in metastatic lesions. Therefore, to estimate ωi, we compare it to
the drug’s cell-kill effect in the primary tumor. More specifically, a chemotherapy dose of ct mg/m
2
on day t reduces the primary tumor cell population by a factor of e−θct , in which θ has a m2/mg
unit (see equation (2.1)). It also reduces the metastatic cell population 24 hours after delivering the
chemotherapy at site i by a factor of e−ωict , and thus ωi has a m2/mg per day unit (see equation
(2.2)). Comparing the two cell-kill factors in the primary tumor and metastatic site i, we set the
cell-kill parameter to ωi = ζiθ, in which ζi (with unit day
−1) is a positive constant depending on
the drug’s concentration and sensitivity of metastatic cells to chemotherapy at the ith site. The
constant ζi = 1 represents a similar drug’s concentration and cell-kill in both the primary tumor
and the metastatic lesion at site i. For other parameters in our model, unless stated otherwise, we
set ξ = 23 and ζi = 1, and use the values specified in Table 2 for pi (i = 1, ..., n).
Parameters Nodes Lung Bone Abdomen
pi 33.3% 40.30% 18.11% 8.29%
Table 2: Metastasis site probabilities based on data presented in [8]
For numerical implementation of our DP algorithm, when there is no radio-sensitization and
either of the conditions stated in Theorem 1 is satisfied (2D state space), we use a discretization
step of 0.1 Gy for the radiation dose fractions. However, the DP algorithm is computationally
more expensive when applied to the cases of radio-sensitizers (4D state space) or dynamic tumor
radio-sensitivity parameters (6D state space). Hence, to ease the computational burden for those
cases, we use discretization steps of 1 Gy and 500 mg/m2 for radiation and chemotherapy dose
fractions, respectively.
4.1 Optimal CRT regimens under static tumor radio-sensitivity parameters
Figure 1 shows the optimal chemotherapy fractionation schedule assuming no radio-sensitization
(ψ = 0) with identical chemotherapy cell-kill parameters at distant metastatic sites (ζ1 = · · · = ζn).
In particular, if ζi (i = 1, . . . , n) is equal at all distant metastatic sites or only a single metastatic
site is considered, then either of the conditions stated in Theorem 1 will always be satisfied. In
that case, the optimal CRT regimen will deliver cmax
(
mg/m2
)
at consecutive treatment sessions
concentrated at either the beginning or the end of the planning horizon.
Figure 2 plots the optimal radiotherapy fractionation schedule for three different values of
[α/β] = {3, 12, 20} and % = {70%, 98%}. We observe that minimization of the metastatic-cell
population in the absence of radio-sensitization leads to a hypo-fractionated schedule with large
initial doses that taper off quickly, regardless of the values for [α/β] and min{[α/β]j /γj}j=1,...,M . If
[α/β] is sufficiently large and % is close to 1, then in order to satisfy inequality (3.10), the optimal
schedule tends to be a semi-hypo-fractionation schedule with large initial doses that taper off slowly.
An extensive sensitivity analysis of the radiotherapy optimal solution to model parameters (T , ξ,
N , Tk) (not reported here) shows that the radiotherapy optimal schedule is robust to perturbations
in these parameters and only depends on [α/β], {[α/β]i /γi}i=1,...,M and %. To study the structure
of the optimal schedules in the absence of radio-sensitization and when none of the conditions stated
in Theorem 1 is satisfied, we use our DP approach with a 3D state space to solve the formulation for
a wide range of values of ξ and pi. We observe that the optimal radiotherapy schedule is determined
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(a) (b)
Figure 1: (a) Schematic of optimal regimens for chemotherapy when assuming same ωi for all
distant metastasis sites and no radio-sensitivity effect. Green and blue regions illustrate whether
it is optimal to immediately initiate chemotherapy or postpone it until the end of the planning
horizon, respectively. (b) Optimal chemotherapy fractionation schedule associated with each region
displayed in Figure 1(a) for planning horizon of five weeks (25 days).
independently of ξ, θ, pi, and ωi and follows the same pattern as displayed in Figure 2 (see black
arrows in Figures 3(a) and 3(b)).
Figure 3 illustrates optimal chemotherapy regimens for different values of pi and ξ when reducing
ζ of the lung to one-third for fixed values of [α/β] = 12 and % = 70%. By reducing the value of
ω in the lung, we ensure that a hypo-fractionated chemotherapy regimen concentrated at the
beginning of therapy minimizes the metastasis population in the lung, whereas a hypo-fractionated
chemotherapy regimen concentrated at the end of the planning horizon minimizes the metastasis
population at three other distant metastatic sites, i.e., nodes, bone, and abdomen. Figure 3(a)
shows that for the case of negligible radio-sensitization, if the probability of metastasis occurrence in
the lung is small (large), then the optimal chemotherapy regimen is dominated by the schedule that
minimizes expected metastatic population at the other three sites (lung), i.e., a hypo-fractionated
chemotherapy regimen concentrated at the end (beginning) of the planning horizon.
Figure 3(b) illustrates how parameter ξ changes the optimal solution in the case where conditions
stated in Theorem 1 do not hold, e.g., ξ ∈ (0.3, 1). In particular, we observe that for high (low)
values of ξ, the overall structure of an optimal solution is dominated by the schedule that minimizes
the expected metastatic population in the lung (nodes, bones, and abdomen). This is due to the
fact that as we increase parameter ξ, there is less incentive to schedule a chemotherapy regimen
concentrating toward the end of the treatment. Hence, the optimal solution favors scheduling
chemotherapy sessions at the beginning of the treatment. Figures 3(c) and 3(d) show that if radio-
sensitization is present (ψ > 0), then the optimal solution escalates the radiation dose in those
fractions in which chemotherapy is administered. In particular, the optimal regimen shifts several
radiotherapy fractions toward the end of the treatment, or schedules several chemotherapy doses at
the beginning of therapy, to benefit from the radio-sensitization mechanism. Additionally, in the
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(a) % = 70% (b) % = 98%
Figure 2: Optimal radiotherapy fractionation schedule for different values of [α/β] in the absence of
radio-sensitivity effect. Black bars in plots (a) and (b) indicate that when [α/β] ≤ minj{[α/β]j /γj},
a hypo-fractionated schedule minimizes both tumor cell population and expected metastatic cell
population. For larger values of [α/β], i.e., [α/β] > minj{[α/β]j /γj}, where an equal-dosage
routine (hyper-fractionated schedule) minimizes the number of tumor cells at the conclusion of
therapy, a hypo-fractionated schedule is still the best solution to minimizing the metastatic cell
population. By increasing the parameter % for tumors with large values of [α/β], in order to satisfy
the BED constraint stated in (3.10), we observe that the resulting fractionation colorblackschedule
is a semi-hypo-fractionated structure with large initial doses that taper off slowly.
18
Figure 3: Optimal chemotherapy regimen when conditions stated in Theorem 1 do not hold. For
these examples, we assume that ωnodes = ωbone = ωabdomen = θ, ωlung = 0.3 × θ, [α/β] = 12,
% = 70% and ψ = {0, 3.21× 10−3}. (a) and (c) Optimal chemotherapy regimen for different values
of plung. (b) and (d) Optimal chemotherapy regimen for different values of ξ. Red and gray arrows
represent chemotherapy doses, whereas black and yellow arrows represent radiotherapy doses. The
arrow position represents the time of dose during the Monday-to-Friday treatment window. The
size of the arrow correlates with the size of the 5-FU or radiation dose, given that the maximum
daily dose cannot exceed 1, 000 m2/mg and 5 Gy for chemotherapy and radiation, respectively.
case of radio-sensitization, the optimal regimen is not sensitive to parameter plung. Based on this
result, we observe that radio-sensitization favors split-course schedules in which radiotherapy and
chemotherapy are administered concurrently, particularly when the metastatic dissemination has a
larger rate and/or higher success probability.
We consider the relative effectiveness of an optimized schedule versus a standard schedule (de-
livering 45 Gy of radiotherapy with 1.8 Gy fractions per day in five weeks and 8, 000 m2/mg of
5-FU with 1, 000 m2/mg per day delivered on Tuesday, Wednesday, Thursday, and Friday of the
first and fourth weeks [42]). In particular, we denote the approximate metastatic population at
n sites under the optimized schedule when setting % = x% in (3.10) by Rxopt and the metastatic
population under a standard uniform fractionation by Rstd. Then we denote the BED delivered to
the primary tumor under optimized and standard schedules by BEDxopt and BEDstd, respectively.
The ratios (Rstd − Rxopt)/Rstd and (BEDstd − BEDxopt)/BEDstd will give us a measure of the pre-
dicted relative reduction in metastasis population and tumor BED, respectively, associated with
using the optimized schedule with % = x% instead of the standard schedule. The results illustrated
in Figure 4 show that the choice of % < 100% can lead to a significant reduction in the metas-
tasis population for all values of [α/β] and ξ. Note that for [α/β] ≥ (mini [α/β]i /γi = 3.3), the
standard regimen is indeed the optimal schedule for the conventional fractionation problem that
maximizes TCP [4, 2], whereas a hypo-fractionated radiotherapy schedule minimizes the metastatic
population size. Hence, Figure 4 illustrates the trade-off between the two conflicting objectives:
(i) minimizing metastatic population size and (ii) maximizing tumor TCP for different [α/β] and
ξ values. One can observe a diminishing return in the reduction of the metastatic population. In
particular, the fractionation solution obtained by setting 1− % = 4% seems to yield an interesting
trade-off between the two objectives beyond which allowing for larger tumor BED reductions, i.e.,
using smaller % = x%, does not lead to any significant gain in metastatic-population reduction
(with the exception of very small values of ξ). Last, for the tumor [α/β] < 3.3, the two objectives
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(a) Varying [α/β], ξ = 2
3
(b) Varying ξ, [α/β] = 12
Figure 4: Trade-off between reduction in metastatic population size and tumor BED relative to
optimal conventional protocols assuming ψ = 0. (a) Maximum metastatic population reduction for
all values of [α/β] examined in this plot is 42% (obtained at % = 0%). (b) Maximum metastatic
population reduction (obtained at % = 0%) for ξ = 0.2, 0.5, and 0.8 examined in this plot is 59%,
48%, and 36%, respectively.
(i) and (ii) are not of a conflicting nature since a hypo-fractionated regimen is desired by both
objectives.
4.2 Optimal CRT regimens under dynamic tumor radio-sensitivity parameters
Figure 5 illustrates optimal CRT regimens for the case in which the tumor radio-sensitivity param-
eters α and β change throughout the treatment course due to tumor re-oxygenation, as shown by
equation (3.15). Under dynamic radio-sensitivity parameters, it is optimal to immediately start
chemotherapy treatment. Additionally, a careful comparison of Figures 3 and 5 reveals that in
contrast to static radio-sensitivity parameters, the structure of the optimal chemotherapy schedule
is robust to changes in model parameters plung and ξ. With respect to the radiotherapy schedule,
it is optimal to deliver a few large fractions at the beginning of the treatment course followed by
several smaller radiation doses in the second and third weeks of therapy. We believe this can be
explained by the increasing order of αt and βt values over the treatment course. In fact, there is
an exponential increase in αt and βt at the beginning of the treatment course, reaching maximum
possible values after delivering a few large fractions of chemotherapy and radiation (within three
or four sessions). Hence, in the optimal schedule, a few large radiation and chemotherapy fractions
are administered at the beginning of the therapy to reduce the tumor size significantly. This leads
to a well-oxygenated tumor at subsequent radiation fractions, rendering the remaining tumor pop-
ulation more susceptible to radiation. Thus, to benefit from this phenomenon, the optimal regimen
administers a set of small radiation fractions during later sessions.
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Figure 5: Optimal CRT regimens with dynamic radio-sensitivity parameters, assuming that
ωnodes = ωbone = ωabdomen = θ, ωlung = 0.3 × θ, αmax = 0.45, [αmax/βmax] = 12, % = 70%,
ψ = 3.21× 10−3, ρ = 108 [55], OERα = 2.5, OERβ = 3 and K = 3.28 [57].
5 Conclusion
In previous work that considers optimal fractionation of chemotherapy and radiotherapy, the goal
has been to maximize the probability of controlling the primary tumor, i.e., local control. Based
on the observation that the majority of cancer fatalities are due to metastatic disease [22], we
consider an alternative objective: design CRT fractionation schedules that minimize the metastatic
population over a sufficiently long window of time. The current work is a significant extension
of our previous work [3], which incorporates multi-site metastatic disease as well as the effect of
chemotherapy through additivity, radio-sensitization, and spatial-cooperation mechanisms. We also
account for tumor re-oxygenation during the course of CRT treatments. We model the metastasis
population as a multi-type non-homogeneous branching process, where each successful metastatic
cell is able to colonize a new tumor at one of several potential distant sites with a known probability.
We are able to derive closed-form solutions to optimal chemotherapy regimens and prove an inter-
esting structure of optimal radiotherapy schedules under easily verified conditions. We numerically
solve this optimization problem using a DP approach.
The resulting optimal schedules have an interesting structure that is quite different from that
observed in the traditional optimal fractionation problem, where the goal is to minimize the local
tumor population at the conclusion of therapy. In the traditional optimal fractionation problem,
it was shown that if the tumor [α/β] ratio is smaller (bigger) than the effective [α/β] ratio of all
OAR, then a hypo-fractionated (hyper-fractionated) schedule is optimal [39]. For the case of CRT
with only additivity and spatial cooperation mechanisms, we proved that the optimal radiotherapy
schedule has a non-increasing structure and that it is optimal to immediately start radiotherapy
treatment. Also, we numerically observed that, a hypo-fractionated radiotherapy regimen with
large initial doses that taper off quickly, minimizes the metastatic population, regardless of tumor
and normal-tissue [α/β] ratios. This result is partially consistent with our previous work, where the
benefit of hypo-fractionation was observed for low values of the tumor [α/β] ratio and high values
of the tumor [α/β] ratio, if the length of time for which we evaluated metastatic risk is short [3]. In
the current work, we observed that if we consider metastases as actively growing tumor cell colonies
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and model them as a non-homogeneous branching process, then regardless of evaluation period and
magnitude of tumor [α/β] ratio, our results show that a hypo-fractionated schedule is nearly always
optimal. We proved that it is always optimal to deliver the maximum drug concentration allowed
during the course of therapy, Cmax.
In the setting of no radio-sensitization (ψ = 0) and static radio-sensitivity parameters we estab-
lished results on the structure of the optimal chemotherapy schedule. When the value θξ, where θ
is the chemotherapy-induced cell-kill at the primary site and ξ is the fractal dimension of the pri-
mary tumor cells capable of metastasizing, is larger than the chemotherapy-induced cell-kill at all
distant sites (maxi=1,...,n{ωi}), the optimal chemotherapy fractionation regimen suggests delivering
Cmax in consecutive days starting from the first day of the planning horizon and administering the
maximum tolerable daily dose at each fraction (concurrent regimen). However, under condition
θξ < mini=1,...,n{ωi}, it is optimal to postpone delivering chemotherapy (or part of the chemother-
apy along with few radiation doses in the presence of radio-sensitization) until the end of treatment
(adjuvant regimen). We observed that when these two conditions are not satisfied, the optimal
regimen is delivering a portion of the total chemotherapeutic agents at the beginning of the plan-
ning horizon and administrating the remaining amount at the end of the therapy. This portion is a
function of θ, ξ, the probability that a successful metastatic cell colonizes at a specific distant site
and ωi for each site.
Our sensitivity analysis for cervical tumors reveals that chemotherapeutic agents with no radio-
sensitization property do not change the optimal radiation fractionation regimens, and vice-versa.
However in the case of active radio-sensitization effect, optimal regimens use an escalated radi-
ation dose on treatment sessions with chemotherapy administrations to benefit from the radio-
sensitization mechanism. This can be compared to an earlier work by Salari et al. where it was
shown that radio-sensitizers may alter the optimal radiation fractionation regimens in a similar
fashion [48]. The benefits of accelerated hypo-fractionation schedules was established numerically,
however radio-sensitizers may postpone delivering few radiotherapy sessions until the end of ther-
apy. Moreover, we consider an extended version of the model with dynamic tumor radio-sensitivity
parameters due to tumor re-oxygenation throughout the treatment course. This leads to optimal
CRT regimens in which the maximum chemotherapy tolerable dose are administered consecutively
at the beginning of treatment; and few large radiation fractions are administered during the first
week of treatment, followed by small doses of radiation in the second and third weeks of therapy.
Interestingly, previous clinical trials (see e.g., [21] for a review) show the benefit of CRT on
overall and progression-free survival, and local and distant control in patients with cervical cancer.
In particular, in clinical trials, it was observed that there is a significant reduction in the rate
of distant metastases in patients diagnosed with cervical cancer treated with both platinum and
non-platinum chemotherapy. This reduction was achieved with a short course of chemotherapy
combined with local treatment. However, there is presently no evidence that neoadjuvant CRT
reduces the incidence of distant metastases [21], which is consistent with our result discussed in
Remark 1 of Section 3.
Our goal here is not to recommend alternative clinical practice but to assist clinicians with
hypothesis generation to design novel CRT fractionation schemes that can be tested in clinical
trials. Our numerical results suggest that using optimal schedules instead of standard regimens has
the potential of reducing the metastatic population by more than 40%, and even for some cases
where the tumor [α/β] ratio is small, we can improve the tumor BED as well.
This paper is an initial step toward developing a new framework to incorporate the risk of
metastatic disease into CRT fractionation decisions. What follows is a discussion of some limitations
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in our framework, which are partly imposed by the lack of clinically established models of the
underlying biological processes. First, it is assumed that the chemotherapeutic drugs administered
at previous treatment fractions do not carry over to the current fraction. However, this may
not necessarily be a valid assumption. Therefore, an important extension of this work will be
to incorporate the effects of previously administered drugs to subsequent fractions. A possible
solution to this could be modeling the effective dose at each fraction as a weighted moving average
of the current and previously administrated doses. Second, the process of metastatic formation and
growth at distant sites was modeled using a non-homogeneous Poisson process and a multi-type
branching process, respectively, which were adopted from previous studies. Those models assume
that the metastatic cells act independently from each other for analytical tractability. However,
metastatic lesions may compete over limited oxygen and nutrient supplies required for growth,
rendering the independence assumption unfavorable. Last, a simple linear model was used to
describe the relationship between the tumor radius and its average oxygen partial pressure. In
particular, the model assumes a dynamic and yet uniform oxygen partial pressure that changes
linearly as the tumor radius shrinks. The assumptions of the uniformity of the oxygen pressure
and its linear relationship to tumor radius may be overly simplistic; however, this linear model
is mainly intended to mimic the increasing behavior of tumor oxygen pressure during therapy, as
suggested by some clinical studies [36].
This work considers the problem of finding radiation and chemotherapy schedules that optimally
minimize the total metastatic populations. While the parameter values for the present work are
focused on cervical cancer, our work is applicable to a wider range of cancers that are treated using
CRT. In particular, we are very eager to investigate the application of our model to additional
cancers in order to find the optimal CRT regimens and study how they may vary across different
cancers. Furthermore, our model is based on the assumption that the total population of the
primary tumor can be accurately approximated with a deterministic function. However, the nature
of tumor response to chemotherapeutic agents and ionizing radiation is stochastic and varies across
different patients. Therefore, a potentially interesting extension of this work could be modeling the
primary tumor response to CRT as a stochastic process.
While the decision problem modeled and solved in this work focuses on cancer treatment, it can
be classified as belonging to a broader category of decision problems related to the optimal control
of spatiotemporal spread of threats. Other forms of threats include infectious diseases, invasive
spices, and Internet security threats. The common goal is to find the optimal combination and
timing of intervention strategies that minimize the threat dispersal, while ensuring that budget
(resource) limitations are met. The intervention strategies may involve, among others, slowing
down the dispersion rate, directly targeting localized outbreaks, and surveillance. The modeling
and solution approach developed in this study can be, in principle, extended and applied to other
decision problems in this category.
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Appendices
A Proof of Lemma 1
Proof. We use contradiction to prove our result. Let the optimal dose vector be ~c′ = {c′1, . . . , c′N}
such that
∑N
t=1 c
′
t < Cmax. Then, we can always construct a feasible solution
~c′′ based on ~c′ that
contradicts the optimality of ~c′. For example, first we set ~c′′ = ~c′, and then for an arbitrary integer
i, 1 ≤ i ≤ N , such that c′i < cmax (note that this integer must exist since we have Cmax < Ncmax),
we set c′′i = min{cmax, c′i + Cmax −
∑N
t=1 c
′
t} and observe that
g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
c′′t ,
N∑
t=1
dtc
′′
t
)
≤ g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
c′t,
N∑
t=1
dtc
′
t
)
and f(~d, ~c′′) ≤ f(~d, ~c′)
since α, β, θ, and ψ are always positive values.
B DP algorithm for the case of static radio-sensitivity parameters
The DP algorithm employs a dynamic table to only store unique and feasible states at each
stage. To this end, all discretized states are enumerated and only those that have unique attribute
combinations (i.e., T.U, T.V, T.S, T.W, T.Uˆ , and T.Vˆ ) are stored. The pseudo code is provided in
Algorithm 1. dmin and cmin represent the discretization step length for radiation and chemotherapy
dose fractions, respectively.
C Proof of Lemma 2
Proof. We use contradiction to prove our result. Assume that there exists an optimal dose vector
~d∗ = {d∗1, . . . , d∗i , . . . , d∗j , . . . , d∗N} such that for some j > i, we have d∗j > d∗i . Now we construct a
new feasible solution ~d′ = {d′1, . . . , d′N}, where d′i = d∗j , d′j = d∗i and d′k = d∗k for k 6= i, j with the
identical drug vector ~c. Since we have ψ = 0, the feasibility constraints and the value of function
g in (3.8) are order independent, i.e., if we change the order of the dose vector, then the resulting
dose vector is still feasible with the same value for function g; hence, ~d′ is a feasible solution to
(3.8)–(3.13) where
g
(
N∑
t=1
d′t,
N∑
t=1
(d′t)
2,
N∑
t=1
ct,
N∑
t=1
d′tct
)
= g
(
N∑
t=1
d∗t ,
N∑
t=1
(d∗t )
2,
N∑
t=1
ct,
N∑
t=1
d∗t ct
)
.
Thus, to prove the result, it is sufficient to show that f(~d′,~c) ≤ f( ~d∗,~c), i.e.,
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αd
′
j+β(d
′
j)
2+(θ−ωi/ξ)cj)− ln 2τd (t−Tk)
+
)
−µit−ωiCmax ≤
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αd
∗
j+β(d
∗
j )
2+(θ−ωi/ξ)cj)− ln 2τd (t−Tk)
+
)
−µit−ωiCmax
for all i = 1, . . . , n. The above inequality is implied by
α
t−1∑
j=1
d′j + β
t−1∑
j=1
(d′j)
2 ≥ α
t−1∑
j=1
d∗j + β
t−1∑
j=1
(d∗j )
2 for all t = 1, . . . , N + 1 and i = 1, . . . , n
We can use the same approach to prove the same result for ~c∗ (see proof of Theorem 1 for more
details).
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Algorithm 1 DP algorithm to solve problem (3.8)–(3.13) with static α and β
1: Create a data table with headers: T={day, U, V, S,W, d, c, obj, id, track}
2: counter ← 1
3: For i ∈ {0 : dmin : dmax} do:
4: For j ∈ {0 : cmin : cmax} do:
5: Create a temporary data table with headers: Ttemp = {day, U, V, S,W, d, c, obj, id, track}
6: Ttemp.day ← 1, Ttemp.U ← i, Ttemp.V ← i2, T.S ← j, Ttemp.W ← i× j, Ttemp.d← i, Ttemp.c← j, Ttemp.id← counter,
Ttemp.track ← 0, and
Ttemp.obj ← Xξ0
n∑
i=1
pie
µiT−ωiCmax
(
1 + e−µi + e−ξ
(
αi+βi2+(θ−ωi/ξ)j+ψij− ln 2τd (2−Tk)
+
)
−2µi
)
7: counter ← counter + 1
8: concatenate(T, Ttemp)
9: For t ∈ {2 : 1 : N} do:
10: Set T ′ = {all rows in table T |T.day = t− 1}
11: For k ∈ {1 : 1 : height(T ′)} do:
12: For i ∈ {0 : dmin : dmax} do:
13: For j ∈ {0 : cmin : cmax} do:
14: Create a temporary data table with headers: Ttemp = {day, U, V, S,W, d, c, obj, id, track}
15: Set
Ttemp.day ← t, Ttemp.U ← T ′.U(k) + i, Ttemp.V ← T ′.V (k) + i2, Ttemp.S ← T ′.S(k) + j, Ttemp.W ← T ′.W (k) + i× j,
Ttemp.d← i, Ttemp.c← j,Ψt,i = µi·(T−t)−ωiCmax−ξ×(αTtemp.U+βTtemp.V+(θ−ωi/ξ)Ttemp.S+ψTtemp.W− ln 2
τd
(t−Tk)+)
Ttemp.obj ← T ′.obj(k) +
{
Xξ0
∑n
i=1 pie
Ψt,i t ≤ N − 1
Xξ0
∑n
i=1 pie
Ψt,i + g(Ttemp.Uˆ , Ttemp.Vˆ , Ttemp.S, Ttemp.W ) t = N
16: If (all feasibility constraints satisfied):
17: Set index = {T.id|T.day = t, T.U = Ttemp.U, T.V = Ttemp.V, T.S = Ttemp.S, T.W = Ttemp.W}
18: If (index == NULL):
19: Ttemp.id← counter
20: Ttemp.track ← T ′.id(k)
21: concatenate(T, Ttemp)
22: counter ← counter + 1
23: Elseif (Ttemp.obj < T.obj(T.id == index)):
24: T.d(T.id == index)← Ttemp.d
25: T.c(T.id == index)← Ttemp.c
26: T.obj(T.id == index)← Ttemp.obj
27: T.track(T.id == index)← T ′.id(k)
28: id∗ ← {T.id|T.obj = min{T.obj|T.day = N}}
29: Return d∗N ← T.d(T.id == id∗), c∗N ← T.c(T.id == id∗)
30: For t ∈ {N − 1 : −1 : 1} do:
31: id∗ ← T.track(T.id == id∗)
32: Return d∗t ← T.d(T.id == id∗), c∗t ← T.c(T.id == id∗)
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D Proof of Theorem 1
Proof. We first prove our results when θξ ≥ maxi=1,...,n ωi. This condition implies that θ − ωi/ξ ≥
0 for all i = 1, . . . , n. First, we use contradiction to show that, in optimality, we must have
c∗1 = · · · = c∗k = cmax for k = bCmax/cmaxc. Assume that there exists an optimal dose vector
~c∗ = {c∗1, . . . , c∗i , . . . , c∗j , . . . , c∗N} such that for some j > i, we have c∗i < cmax and c∗j > 0. Now we
construct a new feasible solution ~c′ = {c′1, . . . , c′N}, where c′i = min{cmax, c∗i +c∗j}, c′j = c∗j − (c′i−c∗i )
and c′k = c
∗
k for k 6= i, j with the identical dose vector ~d. First, note that the drug vector ~c′ is a
feasible solution, since
∑N
t=1 c
′
t =
∑N
t=1 c
∗
t and c
′
t ≤ cmax for t = 1, . . . , N . Second, the value of
function g in (3.8) has the same value for both ~c∗ and ~c′, since
∑N
t=1 c
∗
t =
∑N
t=1 c
′
t and ψ = 0, i.e.,
g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
c∗t ,
N∑
t=1
dtc
∗
t
)
= g
(
N∑
t=1
dt,
N∑
t=1
d2t ,
N∑
t=1
c′t,
N∑
t=1
dtc
′
t
)
.
Thus, to prove that ~c′ results in a smaller objective function, it is sufficient to show that f(~d, ~c′) ≤
f(~d, ~c∗), i.e.,
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αdj+βd
2
j+(θ−ωi/ξ)c′j)− ln 2τd (t−Tk)
+
)
−µit−ωiCmax ≤
N+1∑
t=0
e
−ξ
(∑t−1
j=1(αdj+βd
2
j+(θ−ωi/ξ)c∗j )− ln 2τd (t−Tk)
+
)
−µit−ωiCmax
for all i = 1, . . . , n. The above inequality can be shown if and only if we show the following
inequality for t = 0, . . . , N + 1
− ξ
 t−1∑
j=1
(αdj + βd
2
j + (θ − ωi/ξ)c′j)−
ln 2
τd
(t− Tk)+
− µit− ωiCmax ≤
− ξ
 t−1∑
j=1
(αdj + βd
2
j + (θ − ωi/ξ)c∗j )−
ln 2
τd
(t− Tk)+
− µit− ωiCmax
or equivalently
t−1∑
k=1
(αdk + βd
2
k + (θ − ωi/ξ)c′k) ≥
t−1∑
k=1
(αdk + βd
2
k + (θ − ωi/ξ)c∗k), i = 1, . . . , n
Since both schedules have an identical radiation dose vector, we need to show that
(θ − ωi/ξ)
t−1∑
k=1
c′k ≥ (θ − ωi/ξ)
t−1∑
k=1
c∗k t = 1, . . . , N + 1 and i = 1, . . . , n.
We assume that θ − ωi/ξ ≥ 0 for all i = 1, . . . , n; therefore, the above inequality is implied by
t−1∑
k=1
c′k ≥
t−1∑
k=1
c∗k for all t = 1, . . . , N + 1.
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Note that c′i = min{cmax, c∗i + c∗j}, c′j = c∗j − (c′i − c∗i ) and c′k = c∗k for j > i and k /∈ i, j; therefore,
we have c′i > c
∗
i , which implies that
∑l
t=1 c
′
t >
∑l
t=1 c
∗
t for l : i ≤ l < j and
∑l
t=1 c
′
t =
∑l
t=1 c
∗
t for
l ≥ j and l < i.
Next, note that as a result of Lemma 1, we know that
∑N
t=1 c
∗
t = Cmax. Hence, we can
repeat the above procedure to improve the optimal solution until we get c∗1 = · · · = c∗k = cmax
for k = bCmax/cmaxc, where no more improvement can be achieved. At this step, we have two
scenarios: first, bCmax/cmaxc ∈ N, where we must have c∗k+1 = · · · = c∗N = 0, which proves our
result; second, bCmax/cmaxc 6= Cmax/cmax, where
∑N
t=k+1 ct = Cmax − kcmax < cmax. In this case,
by using the same contradiction as before, we can show that if we choose ck+1 < Cmax − kcmax,
then we can always construct a feasible solution with a smaller objective function.
We can use a similar approach when θξ < mini=1,...,n ωi. In this case, we have θ−ωi/ξ < 0, i =
1, . . . , n. Therefore, for any schedule with c∗i < cmax and c
∗
j > 0 for i > j, we can construct a new
feasible solution ~c′ = {c′1, . . . , c′N}, where c′i = min{cmax, c∗i + c∗j} > c∗i , c′j = c∗j − (c′i − c∗i ) < c∗j and
c′k = c
∗
k for k 6= i, j with a smaller objective function. Similar to the previous case, here we require
that
t−1∑
k=1
(αdk + βd
2
k + (θ − ωi/ξ)c′k) ≥
t−1∑
k=1
(αdk + βd
2
k + (θ − ωi/ξ)c∗k), i = 1, . . . , n
since θ − ωi/ξ < 0 i, which equivalently shows that
t−1∑
k=1
c′k ≤
t−1∑
k=1
c∗k for all t = 1, . . . , N + 1.
This inequality is implied by
∑l
t=1 c
′
t <
∑l
t=1 c
∗
t for l : j ≤ l < i and
∑l
t=1 c
′
t =
∑l
t=1 c
∗
t for l ≥ i
and l < j. The rest is similar to the situation where θξ > maxi=1,...,n ωi.
E DP algorithm for the case of dynamic radio-sensitivity parameters
The structure of the 6D DP algorithm is similar to the 4D case. However, we need to store infor-
mation related to two additional state dimensions, which are {Uˆt, Vˆt}, leading to a larger number
of rows and columns in our DP table. Hence, the 6D DP algorithm has a higher computational
and space complexity compared to the 4D case. To ease this additional burden, we derive and
use the following structural results on the optimal solution to significantly reduce the height of the
DP table by only storing information related to promising states and skipping those that lead to
sub-optimal solutions.
Lemma 3. Consider two arbitrary states at time stage t, B1,t = {u1, v1, s1, w1, uˆ1, vˆ1} and B2,t =
{u2, v2, s2, w2, uˆ2, vˆ2} where Jˆ(B2,t) ≤ Jˆ(B1,t). Then we can discard the row associated with state
B1,t in our DP table if u2 ≤ u1, v2 ≤ v1, s1 = s2, w2 ≥ w1, uˆ2 ≥ uˆ1 and vˆ2 ≥ vˆ1.
Proof. We prove this result by contradiction. Suppose there exists an optimal path initiated from
B1,t, then we construct a solution using B2,t with a smaller objective value. To this end, let the
optimal solution associated with B1,t be ~d∗ = {d∗1, . . . , d∗t , . . . , d∗N} and ~c∗ = {c∗1, . . . , c∗t , . . . , c∗N}
and the path resulting in Jˆ(B2,t) be {d′1, . . . , d′t} and {c′1, . . . , c′t}. Then we can construct solution
{d′1, . . . , d′t, d∗t+1, . . . , d∗N} and {c′1, . . . , c′t, c∗t+1, . . . , c∗N} with a smaller or equal objective value. It
suffices to establish that
Jˆ(B2,k) ≤ Jˆ(B1,k),∀k = t+ 1, . . . , N + 1
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We show the validity of the inequality above for k = t+ 1, and the proof for k = t+ 2, . . . , N + 1
is similar. The inequality Jˆ(B2,t+1) ≤ Jˆ(B1,t+1) is equivalent to
Jˆ(B2,t) +Xξ0
n∑
i=1
pie
−ξ×Ψˆ2,i,t+1+µi(T−t−1)−ωiCmax ≤ Jˆ(B1,t) +Xξ0
n∑
i=1
pie
−ξ×Ψˆ1,i,t+1+µi(T−t−1)−ωiCmax .
Note that the above inequality is implied by
Jˆ(B2,t) ≤ Jˆ(B1,t) and Ψˆ2,i,t+1 ≥ Ψˆ1,i,t+1 ∀i.
The inequality Ψˆ2,i,t+1 ≥ Ψˆ1,i,t+1 follows from
uˆ2 + α2,t+1d
∗
t+1 + vˆ2 + β2,t+1(d
∗
t+1)
2 + (θ − ωi/ξ)(s2 + c∗t+1) + ψ(w2 + d∗t+1c∗t+1) ≥ (6.18)
uˆ1 + α1,t+1d
∗
t+1 + vˆ1 + β1,t+1(d
∗
t+1)
2 + (θ − ωi/ξ)(s1 + c∗t+1) + ψ(w1 + d∗t+1c∗t+1).
Note that we have s1 = s2, w2 ≥ w1, uˆ2 ≥ uˆ1, and vˆ2 ≥ vˆ1, and we can conclude that y2,t ≥ y1,t.
Therefore, to prove inequality (6.18), it suffices to show
α2,t+1d
∗
t+1 + β2,t+1(d
∗
t+1)
2 ≥ α1,t+1d∗t+1 + β1,t+1(d∗t+1)2.
Since we always have OERα ≥ 1 and OERβ ≥ 1, and the inequality y2,t ≥ y1,t holds, we can use
(3.15) to complete the proof
α2,t+1 ≥ α1,t+1 and β2,t+1 ≥ β1,t+1.
We next use the result of Lemma 1 to discard another set of sub-optimal states during the state
enumerations at each stage.
Observation 1: Consider an arbitrary state at time stage t, Bt = {Ut, Vt, St,Wt, Uˆt, Vˆt}. Then
we can discard Bt if (N − t)cmax < Cmax − St.
Using the above results, we use Algorithm 2 to solve problem (3.8)–(3.13) with dynamic radio-
sensitivity parameters α and β.
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Algorithm 2 DP algorithm to solve problem (3.8)–(3.13) with dynamic α and β
1: Create a data table with headers: T={day, U, V, S,W, Uˆ, Vˆ , d, c, obj, id, track}
2: y1 ← ymax − ι× 3
√
3X0
4piρ
, counter ← 1 and compute α1 and β1 based on (3.15)
3: For i ∈ {0 : dmin : dmax} do:
4: For j ∈ {0 : cmin : cmax} do:
5: Create a temporary data table with headers: Tte = {day, U, V, S,W, Uˆ, Vˆ , d, c, obj, id, track}
6: Tte.day ← 1, Tt.U ← i, Tte.V ← i2, T.S ← j, Tte.W ← i × j, Tte.Uˆ ← α1 × i, Tte.Vˆ ← β1 × i2, Tte.d ← i, Tte.c ← j,
Tte.id← counter, Tte.track ← 0, and
Tte.obj ← Xξ0
n∑
i=1
pie
µiT−ωiCmax
(
1 + e−µi + e−ξ
(
α1i+β1i
2+(θ−ωi/ξ)j+ψij− ln 2τd (2−Tk)
+
)
−2µi
)
7: counter ← counter + 1
8: concatenate(T, Tte)
9: For t ∈ {2 : 1 : N} do:
10: Set T ′ = {all entities in table T |T.day = t− 1}
11: For k ∈ {1 : 1 : height(T ′)} do:
12: yt ← ymax − ι× 3
√
3X0
4piρ
exp
(
− 1
3
(
T ′.Uˆ(k) + T ′.Vˆ (k) + θT ′.S(k) + ψT ′.W (k) + ln 2
τd
(t− Tk)+
))
and compute αt and
βt using equations (3.15)
13: For i ∈ {0 : dmin : dmax} do:
14: For j ∈ {0 : cmin : cmax} do:
15: Create a temporary data table with headers: Tte = {day, U, V, S,W, Uˆ, Vˆ , d, c, obj, id, track}
16: Set
Tte.day ← t, Tte.U ← T ′.U(k) + i, Tte.V ← T ′.V (k) + i2, Tte.S ← T ′.S(k) + j, Tte.W ← T ′.W (k) + i× j,
Tte.Uˆ ← T ′.Uˆ(k) + i× αt, Tte.Vˆ ← T ′.Vˆ (k) + i2 × βt, Tt.d← i, Tte.c← j,
Ψi,t = µi · (T − t)− ωiCmax − ξ × (Tte.Uˆ + Tte.Vˆ + (θ − ωi/ξ)Tte.S + ψTte.W − ln 2
τd
(t− Tk)+)
Tte.obj ← T ′.obj(k) +
{
Xξ0
∑n
i=1 pie
Ψi,t t ≤ N − 1
Xξ0
∑n
i=1 pie
Ψi,t + gˆ(Tte.Uˆ , Tte.Vˆ , Tte.S, Tte.W ) t = N
17: If (all feasibility constraints satisfied and (N − t)cmax ≥ Cmax − Tte.S):
18: Set
~index = {∀ T.id|T.day = t, Tte.U ≤ T.U, Tte.V ≤ T.V, Tte.S = T.S, Tte.W ≥ T.W, Tte.Uˆ ≥ T.Uˆ , Tte.Vˆ ≥ T.Vˆ }
19: If ( ~index == NULL):
20: Tte.id← counter
21: Tte.track ← T ′.id(k)
22: concatenate(T, Tte)
23: counter ← counter + 1
24: Else:
25: For k ∈ ~index
26: If (Tte.obj ≤ T.obj(T.id == index(k))):
27: Remove row with ID index(k) from table T
28: check ← 1
29: If check=1
30: Tte.id← counter
31: Tte.track ← T ′.id(k)
32: concatenate(T, Tte)
33: counter ← counter + 1
34: id∗ ← {T.id|T.obj = min{T.obj|T.day = N}}
35: Return d∗N ← T.d(T.id == id∗), c∗N ← T.c(T.id == id∗)
36: For t ∈ {N − 1 : −1 : 1} do:
37: id∗ ← T.track(T.id == id∗)
38: Return d∗t ← T.d(T.id == id∗), c∗t ← T.c(T.id == id∗)
34
